Randomised masked clinical trial of the MGDRx EyeBag for the treatment of meibomian gland dysfunction-related evaporative dry eye.
Randomised masked clinical trial of the MGDRx EyeBag for the treatment of meibomian gland dysfunction-related evaporative dry eye.
复制标题
DOI：
10.1136/bjophthalmol-2014-305220
复制
发表时间：
2014-12
期刊：
影响因子：
--
通讯作者：
Wolffsohn JS
中科院分区：
文献类型：
--
作者：
Bilkhu PS;Naroo SA;Wolffsohn JS
旨在研究 MGDRx EyeBag（The Eyebag Company，哈利法克斯，英国）眼睑加热装置的功效和安全性。 25 名确诊为睑板腺功能障碍 (MGD) 相关蒸发性干眼症的患者被纳入一项随机、单盲、对侧临床试验。测试眼睛接受加热装置；使用非加热设备控制眼睛，每天两次，每次 5 分钟，持续 2 周。在基线和随访时进行疗效（眼部症状、非侵入性破裂时间、脂质层厚度、渗透压、睑板腺脱落和功能）和安全性（视力、角膜地形图、结膜充血和染色）测量。随后的患者设备使用情况和眼部舒适度在 6 个月时确定。对于所有测量，测试眼和对照眼之间的基线差异均不具有统计学显着性 (p>0.05)。 2 周后，测试眼的所有功效测量均出现统计学上显着的改善（p<0.05）。视力和角膜地形图不受影响（p>0.05）。所有患者在 6 个月后都保持了较高的眼部舒适度 (p<0.05)，尽管每月继续使用 1-8 次的患者获益更大 (p<0.001)。 MGDRx EyeBag 是一种安全有效的治疗 MGD 相关蒸发性干眼症的设备。在偶尔再治疗的帮助下，主观获益至少持续 6 个月。 NCT01870180。
To investigate the efficacy and safety of the MGDRx EyeBag (The Eyebag Company, Halifax, UK) eyelid warming device. Twenty-five patients with confirmed meibomian gland dysfunction (MGD)-related evaporative dry eye were enrolled into a randomised, single masked, contralateral clinical trial. Test eyes received a heated device; control eyes a non-heated device for 5 min twice a day for 2 weeks. Efficacy (ocular symptomology, non-invasive break-up time, lipid layer thickness, osmolarity, meibomian gland dropout and function) and safety (visual acuity, corneal topography, conjunctival hyperaemia and staining) measurements were taken at baseline and follow-up. Subsequent patient device usage and ocular comfort was ascertained at 6 months. Differences between test and control eyes at baseline were not statistically significant for all measurements (p>0.05). After 2 weeks, statistically significant improvements occurred in all efficacy measurements in test eyes (p<0.05). Visual acuity and corneal topography were unaffected (p>0.05). All patients maintained higher ocular comfort after 6 months (p<0.05), although the benefit was greater in those who continued usage 1–8 times a month (p<0.001). The MGDRx EyeBag is a safe and effective device for the treatment of MGD-related evaporative dry eye. Subjective benefit lasts at least 6 months, aided by occasional retreatment. NCT01870180.
登录
查看更多内容
影响因子：
1.4
作者：
Ishida, Reiko;Matsumoto, Yukihiro;Tsubota, Kazuo
通讯作者：
Tsubota, Kazuo
DOI：
10.1097/01.icl.0000060998.20142.8d
发表时间：
2003-04-01
期刊：
Eye & contact lens
影响因子：
--
作者：
Olson, Mary Catherine;Korb, Donald R;Greiner, Jack V
通讯作者：
Greiner, Jack V
影响因子：
2.8
作者：
MATHERS, WD;SHIELDS, WJ;JESTER, JV
通讯作者：
JESTER, JV
睑板腺功能障碍国际研讨会： 诊断小组委员会的报告
影响因子：
4.4
作者：
Tomlinson, Alan;Bron, Anthony J.;Dogru, Murat
通讯作者：
Dogru, Murat
影响因子：
4.4
作者：
Knop, Erich;Knop, Nadja;Sullivan, David A.
通讯作者：
Sullivan, David A.